Du är här


Swedish Orphan Biovitrum AB (publ): Sobi's Orfadin® oral suspension granted European patent

Swedish Orphan Biovitrum AB (publ)(Sobi) today announced that the European
Patent Office (EPO) has decided to grant a European patent for the Orfadin®
(nitisinone) oral suspension formulation, which was approved by the European
Commission for the treatment of Hereditary Tyrosinaemia type-1 (HT-1) in
2015. HT-1 is a rare genetic disease that affects infants and children. It is
progressive and may result in liver and kidney complications and can be fatal
if untreated.

"Sobi has a long-term commitment to the HT-1 community and work to
continuously improve the available treatment options. The oral suspension
formulation is a demonstration of this commitment to the needs of the infants
and children diagnosed with HT-1 early in life", said Geoffrey McDonough, CEO
and President of Sobi. "The oral suspension of Orfadin for paediatric use
facilitates dosing accuracy and simplifies ease of use."

Before pharmacological treatment was available, less than one third of infants
diagnosed with HT-1 before two months of age lived past their second
birthday.[i]Treatment with Orfadin combined with dietary restriction of
tyrosine and phenylalanine and more widespread new-born screening, leading to
early diagnosis have dramatically improved outcomes for HT-1 patients.[ii]

The patent, granted in January 2016, will confer protection to the Orfadin
oral suspension formulation in each contracting and extension state to the
European Patent Convention (EPC).


About Orfadin®

People with Hereditary Tyrosinaemia type-1 (HT-1) have problems breaking down
an amino acid called tyrosine. Toxic by-products are formed and accumulate in
the body, which can cause liver, renal and neurological complications.
Orfadin® (nitisinone) blocks the breakdown of tyrosine, thereby reducing the
amount of toxic by-products in the body. In the most common form of the
disease, symptoms arise within the first six months of the child's life.
Patients must maintain a special diet in combination with Orfadin treatment
as tyrosine is not adequately broken down. Approximately 1,000 persons are
identified as living with HT-1 today. Orfadin is a proprietary product and is
developed by and marketed globally by Sobi.

About Sobi(TM)

Sobi is an international specialty healthcare company dedicated to rare
diseases. Sobi's mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets
a portfolio of specialty and rare disease products for partner companies
across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion
(USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on
NASDAQ OMX Stockholm. More information is available at www.sobi.com.

For more information please contact

| Media relations Investor relations |
| Oskar Bosson, Head of Corporate Communications Jörgen Winroth, Vice President, Head of Investor Relations |
| T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 |
| oskar.bosson@sobi.com jorgen.winroth@sobi.com |

---------------------------------------[i]van Spronsen FJ, Thomasse Y, Smit GP, et al. Hepatology.
[ii]Orfadin EPAR: Product information 25/07/2013 Orfadin -EMEA/H/C/000555

004e_Orfadin liquid patent


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.